In other phase II and III studies, addition of sorafenib to docetaxel [139] or capecitabine (a prodrug for fluorouracil) [140], respectively, in advanced or metastatic HER2-negative breast cancer patients did not improve the effect of chemotherapy and only increased the rate of toxicity. The gene discussed is ERBB2; the disease is breast carcinoma.